16th Jun 2011 17:59
For immediate release | 16 June 2011 |
Alliance Pharma plc
TR-1: Notification of major interest in shares
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: | Alliance Pharmaplc | |||
2 Reason for the notification (please tick the appropriate box or boxes): | ||||
An acquisition or disposal of voting rights | ||||
An acquisition or disposal of qualifying financial instruments which may result in theacquisition of shares already issued to which voting rights are attached | ||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | ||||
An event changing the breakdown of voting rights | ||||
Other (please specify): | On market transfer between direct and indirect funds | √ | ||
3. Full name of person(s) subject to thenotification obligation: | Aviva plc & its subsidiaries | |||
4. Full name of shareholder(s) (if differentfrom 3.): | Registered Holder:
BNY Norwich Union Nominees Limited 3,484,351* Chase (GA Group) Nominees Limited 20,832,404*
*denotes direct interest
| |||
5. Date of the transaction and date onwhich the threshold is crossed orreached: | 15 June 2011 | |||
6. Date on which issuer notified: | 16 June 2011 | |||
7. Threshold(s) that is/are crossed orreached: | 9% to 10% Change at Direct Interest Level | |||
8. Notified details: | ||||||||||||||||
A: Voting rights attached to shares | ||||||||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | ||||||||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights | ||||||||||||
Direct | Direct | Indirect | Direct | Indirect | ||||||||||||
Ordinary SharesGB0031030819 | Direct: 23,814,269 Indirect: 502,486 | Direct: 23,814,269 Indirect: 502,486 | 24,316,755 | 24,316,755 | Nil Held | 10.16% | Nil Held | |||||||||
B: Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Expirationdate | Exercise/Conversion Period | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | ||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Exercise price | Expiration date | Exercise/Conversion period | Number of voting rights instrument refers to
| % of voting rights
| |||||||||||
| Nominal | Delta | ||||||||||||||
Total (A+B+C) | ||||||||||||||||
Number of voting rights | Percentage of voting rights | |||||||||||||||
24,316,755 | 10.16% | |||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: | ||
The voting rights are managed and controlled byAviva Investors Global Services Limited, with the following chain of controlled undertakings:-
Aviva Investors Global Services Limited: ·; Aviva plc (Parent Company) ·; Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) ·; Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) ·; Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
| ||
Proxy Voting: | ||
10. Name of the proxy holder: | See Section 4 | |
11. Number of voting rights proxy holder will ceaseto hold: | ||
12. Date on which proxy holder will cease to holdvoting rights: | ||
13. Additional information: | Figures are based on a revised total number of voting rights of 239,394,534 per the company's Exercise of Share Options Announcement of 10 June 2011. | |
14. Contact name: | Neil Whittaker, Aviva plc | |
15. Contact telephone number: | 01603 684420 | |
Related Shares:
Alliance PharmaAviva